Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$5.71
-$0.58(-10.41%)
At close: 4:00 PM EST
$5.71
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$1.73 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)671.05K
Market Cap
$177.02M
Enterprise Value$144.64M
Total Cash (Recent Filing)$116.69M
Total Debt (Recent Filing)$115.00K
Price to Earnings (P/E)―
Beta2.93
Next Earnings
Mar 30, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding31,001,108
10 Day Avg. Volume396,685
30 Day Avg. Volume671,047
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio-3.32
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.38
Forecast
1Y Price Target
$26.14Price Target Upside357.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.92
Revenue Forecast (FY)$272.73K
Bulls Say, Bears Say
Bulls Say
China Regulatory ApprovalRegulatory review in China could lead to approval that triggers milestone payments and royalties, improving revenue visibility and creating a commercial pathway in a large market.
Scientific Validation And Biomarker SensitivityAI-based digital pathology detected fibrosis improvements that conventional methods missed, and preclinical combination data showed larger anti-fibrotic effects, strengthening the scientific rationale for the drug combination.
Strategic Licensing For Co-formulationA global license for a novel resmetirom active ingredient from a major supplier enables potential co-formulation with denifanstat and reduces intellectual property obstacles for a fixed-dose combination strategy.
Bears Say
Clinical And Regulatory Development RiskProgression to mid-stage trials depends on favorable early data and alignment with regulators, creating uncertainty that could delay development or prevent advancement.
Conflict Of Interest In CoverageDisclosure of business relationships between covering firms and covered companies may present a conflict of interest that could affect the perceived objectivity of analyst reports and investor confidence.
Single-pill Availability And Timeline RiskPlanned use of separate tablets in mid-stage studies means a single-pill co-formulation would only be tested later, potentially delaying patient access to a combined therapy and related commercial benefits.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $177.02M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Mar 30, 2026 which is in 28 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Nov 13, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.386 by -$0.014.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.43.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.386. Following the earnings report the stock price went down -12.245%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.14 (357.79% Upside)
$26.14 (357.79% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 549.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
58.17%
12-Months-Change
Fundamentals
Return on Equity
-39.78%
Trailing 12-Months
Asset Growth
-26.53%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$26.14
▲(357.79% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.00% Insiders
5.91% Mutual Funds
5.57% Other Institutional Investors
73.67% Public Companies and Individual Investors